NCT05362110View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

June 5, 2023

Study Completion Date

June 5, 2023

Conditions
Hypertension
Interventions
DRUG

HCP1803-3

Take it once daily for 8 weeks orally.

DRUG

RLD2002

Take it once daily for 8 weeks orally.

DRUG

HPP2003-3

Placebo drug. Take it once daily for 8 weeks orally.

DRUG

HPP2004

Placebo drug. Take it once daily for 8 weeks orally.

Trial Locations (1)

10326

Donggguk University Ilsan Hospital, Goyang-si

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05362110 - A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension | Biotech Hunter | Biotech Hunter